Results 171 to 180 of about 36,345 (262)

Limited Efficacy of Autologous Mesenchymal Stromal Cell Injections in Immunomodulatory‐Dependent Dogs With Aqueous Deficient Dry Eye Disease

Veterinary Ophthalmology, Volume 29, Issue 5, September 2026.
ABSTRACT Objective Aqueous deficient dry eye disease (ADDE) results from a quantitative reduction in aqueous tears. We sought to determine the clinical effect of autologous mesenchymal stromal cell (MSC) injections into the region of the lacrimal gland and the gland of the third eyelid in immunomodulatory‐dependent ADDE‐affected dogs. Methods Dogs (n = 
Brian C. Leonard, Shin Ae Park, Sun Young Kim, Kei Hayashi, Sara M. Thomasy, Vanessa Rozo, Monica J. Motta, Dori L. Borjesson, Christopher J. Murphy, Kathryn L. Good   +9 more
wiley   +1 more source

Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone. [PDF]

Cardiooncology
Bryce AH, Nimke D, Young C, Shao Q, Rozario N, Kamdar P, Ivanova J, Varghese I, Touya M.   +8 more
europepmc   +1 more source

Sustained Tear Film Exposure After Parenteral Cefovecin Administration in Dogs: Pharmacokinetics and Relevance to Canine Bacterial Keratitis

Veterinary Ophthalmology, Volume 29, Issue 5, September 2026.
ABSTRACT Objective To characterize the tear film pharmacokinetics of parenterally administered cefovecin (Convenia) and compare tear concentrations with the minimum inhibitory concentrations (MICs) of common ocular pathogens. Animals Studied Six healthy research‐bred Beagles.
Meredith R. McClure, Lionel Sebbag, David J. Borts, Rachel A. Allbaugh, Jessica L. Payne, Melissa A. Kubai   +5 more
wiley   +1 more source

Longitudinal renal function following [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer. [PDF]

Eur J Nucl Med Mol Imaging
Cockcroft M, Ferguson T, Meehan K, Al-Ogaili Z.   +3 more
europepmc   +1 more source

How low do you need to go? Association between various prostate‐specific antigen response measures and clinical outcomes in metastatic castration‐sensitive prostate cancer in the Veterans Health Administration data

Cancer, Volume 132, Issue 16, 15 August 2026.
In a retrospective analysis of Veterans Health Administration data for patients with metastatic castration‐sensitive prostate cancer (mCSPC), achieving a prostate‐specific antigen (PSA) of <0.2 ng/mL (whether or not a PSA decline of 90% was reached) within 9 months of initiating androgen deprivation therapy (ADT) ± other treatments was associated with ...
Stephen J. Freedland, Wei Gao, Maëlys Touya, Hongbo Yang, David Russell, Jingyi Chen, Grace Chen, Jasmina I. Ivanova   +7 more
wiley   +1 more source

Sequential nanocatalytic therapy and lysosomal dysfunction for overcoming castration-resistant prostate cancer. [PDF]

Bioact Mater
Di J, Lee W, Xu Y, Kong H, Zhou F, Xu J, Chen X, Lao YH, Shao D, Xie X, Yao H, Tao Y, Li M.   +12 more
europepmc   +1 more source

Radiation safety management for stereotactic body radiation therapy incidentally concurrent with Pluvicto® (Lu‐177) therapy ‐ a case report

Journal of Applied Clinical Medical Physics, Volume 27, Issue 8, August 2026.
Abstract A patient with castration‐resistant prostate cancer (CRPC) was referred to our clinic seeking palliative management of a painful metastasis in the left pelvis. At the time of referral, the patient was receiving [177Lu]Lu‐PSMA 617 (Pluvicto®) therapy at an outside institution, with the next scheduled administration approaching within days.
Dongxu Wang, Bae P. Chu, Maria F. Chan, Jeonghoon Park, Yolanda Scott, Puneeth Iyengar, Matthew Williams   +6 more
wiley   +1 more source

Nicotinamide N-methyltransferase as a therapeutic target in taxane-resistant castration-resistant prostate cancer. [PDF]

Cell Death Discov
Cevatemre B, Karyemez E, Bulut I, Syed H, Gönen M, Baykal AT, Bagci-Onder T, Acilan C.   +7 more
europepmc   +1 more source

A Non‐Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non‐Small Cell Lung Cancer

Advanced Science, Volume 13, Issue 46, 17 August 2026.
A non‐canonical core transcriptional regulatory circuit, composed of ID3, SMAD3, and NR2F2, drives Osimertinib resistance in non‐small cell lung cancer through super‐enhancer‐mediated activation of EPAS1, which couples neuroendocrine differentiation with ferroptosis evasion.
Aochu Liu, Zhenguo Liu, Lizhen Jiang, Andong Huang, Xinqing Lin, Xinyue Li, Bingyuan Liu, Shiwen Hu, Qiang Pan, Junjun Huang, Liyuan Yin, Liling Jiang, Wei Yi, Wenjun Mao, Yueyuan Zheng, Xianping Shi   +15 more
wiley   +1 more source

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. [PDF]

J Immunother Cancer
Li C, Madan RA, Lee MJ, Lee S, Sato N, Rastogi S, Shrestha R, Aragon-Ching JB, Goswami M, Donahue RN, Cordes LM, Baj A, Seo CCY, Terrigino NT, Bright JR, Hennigan ST, King IM, Trostel SY, Fenimore JM, Liu Y, Calzone KA, Schlom J, Gulley JL, Dahut WL, Figg WD, Sowalsky AG, Lee JM, Karzai F.   +27 more
europepmc   +1 more source